
A systematic review and meta-analysis of 15 studies on HPV-negative oropharyngeal squamous cell carcinoma (OPSCC) found that surgery with adjuvant therapy resulted in 84% 2-year and 72% 5-year overall survival (OS). For transoral surgery (TOS), the 2-year and 5-year OS were 87% and 82%, respectively. Disease-free survival (DFS) was 77% at 2 years and 59% at 5 years. These results highlight surgery, especially TOS, as an effective treatment for HPV-negative OPSCC.
Like
Save
Share